ArticleToxicology research2019
Cell cycle and transmembrane mitochondrial potential analysis after treatment with chromium(iii), iron(iii), molybdenum(iii) or nickel(ii) and their mixtures.
Article in Toxicology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 20 citations in OpenAlex.
- Plant-Mediated Production of Antibacterial Nanomaterials Fulfilling a Reactive Oxygen Species Strategy.International journal of molecular sciences · 2026Review
- Genotoxic Effects of Chromium(III) and Cobalt(II) and Their Mixtures on the Selected Cell Lines.International journal of molecular sciences · 2025Article
- The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model.Cancers · 2023Article
- Ion Release and Surface Changes of Nickel-Titanium Archwires Induced by Changes in the pH Value of the Saliva-Significance for Human Health Risk Assessment.Materials (Basel, Switzerland) · 2022Article
- Risk Assessment of Oxidative Stress Induced by Metal Ions Released from Fixed Orthodontic Appliances during Treatment and Indications for Supportive Antioxidant Therapy: A Narrative Review.Antioxidants (Basel, Switzerland) · 2021Review
- Nickel carcinogenesis mechanism: cell cycle dysregulation.Environmental science and pollution research international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to examine the effect of chromium(iii), iron(iii), molybdenum(iii) and nickel(ii) and their combinations on the cell cycle and mitochondrial transmembrane potential (MTP) in BALB/3T3 and HepG2 cells. A statistically significant dose related decrease of the percentage of cells in the G0/G1 and S phases was observed. However, a statistically significant dose related increase of the percentage of cells in the G2/M phase after exposure to chromium(iii), nickel(ii) or molybdenum(iii) at 200-1000 μM concentrations in both cell lines was observed. Moreover, an increase of the percentage of cells in the subG1 phase was observed. In both cell lines a statistically significant dose related decrease of the percentage of cells in the G2/M phase after exposure to iron(iii) at 200-1000 μM concentrations was observed. However, a statistically significant dose related increase of the percentage of cells in the G0/G1 phase after exposure to iron(iii) at 200-1000 μM concentrations was observed. A concentration dependent statistically significant decrease in the level of the MTP was observed in both cell lines after exposure to chromium(iii), iron(iii), nickel(ii) and molybdenum(iii). The results obtained from both cell lines show that HepG2 cells are more sensitive when compared to BALB/3T3 cells. Additions of Cr(iii) at 200 μM plus Fe(iii) at 1000 μM showed a synergistic effect on the cell cycle and MTP. In the case of Cr(iii) at 200 μM plus Mo(iii) at 1000 μM, an antagonistic effect was observed in both analyses. In the case of Cr(iii) at 1000 μM plus Mo(iii), Ni(ii) and Fe(iii) at 200 μM, no changes in the percentage of cells in all phases were observed in both cell lines in both analyses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.